Monitor the sNDA submission for aficamten in nHCM expected in Q4 2026 and any FDA acceptance or review timeline. The positive remodeling and safety data incrementally support the nHCM approval case but do not change near-term revenue trajectory.
Drug in focus
CYTK drug pipeline →MYQORZO
▲ Bullish Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
- Next catalyst
- None dated
What to watchThe FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $55.14entry
- T+1 · 7d ago +1.89%α +2.25% · $56.18
- T+5 · 16h ago −3.57%α −1.88% · $53.17
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cytokinetics presented new aficamten data at HCMS/AHA 2026, including positive cardiac remodeling and patient-reported outcomes from the ACACIA-HCM nHCM trial and long-term safety from FOREST-HCM. The data support the upcoming sNDA filing for aficamten in non-obstructive HCM, but no regulatory decision or commercial update was announced.
Key Facts
- ACACIA-HCM CMR sub-study showed statistically significant reductions in LVMI and wall thickness at 36 weeks (p<0.001)
- ACACIA-HCM KCCQ-OSS analysis showed 4.0-point greater improvement vs placebo at Week 36
- FOREST-HCM data: 2.9% of 410 oHCM patients had LVEF <50%, none <40%, no heart failure hospitalizations or deaths
- Company plans to submit sNDA for aficamten in nHCM in Q4 2026
- MYQORZO is already approved in US, China, EU, UK, Canada for oHCM
Financial Impact
No new financial guidance or revenue data provided; Q3 MYQORZO net product revenue was $44.5M per prior 8-K
Risk Factors
- sNDA may not be accepted or approved by FDA
- Competition from other HCM therapies (e.g., mavacamten)
- Long-term safety data from FOREST-HCM shows low but non-zero LVEF reduction risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398296 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers